Integrated Filing — IndAS



General information about company

Scrip Code 500124
NSE Symbol DRREDDY
MSEI Symbol NOTLISTED
ISIN INE089A01031
Name of company Dr. Reddy's Laboratories Limited
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2025
Date of end of financial year 31-03-2026
Date of board meeting when results were approved 12-05-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 23-03-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Fourth quarter
Nature of report standalone or consolidated Consolidated
Whether results are audited or unaudited for the quarter ended Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Multi segment
Description of single segment
Start date and time of board meeting 12-05-2026   14:00:00
End date and time of board meeting 12-05-2026   15:47:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-01-2026 01-04-2025
B Date of end of reporting period 31-03-2026 31-03-2026
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Consolidated Consolidated
1 Income
Revenue from operations 7,54,640.00 33,70,020.00
Other income 47,540.00 1,35,840.00
Total income 8,02,180.00 35,05,860.00
2 Expenses
(a) Cost of materials consumed 1,19,860.00 6,50,120.00
(b) Purchases of stock-in-trade 1,65,770.00 6,16,160.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade 35,640.00 (42,360.00)
(d) Employee benefit expense 1,44,680.00 5,99,090.00
(e) Finance costs 10,570.00 37,380.00
(f) Depreciation, depletion and amortisation expense 55,710.00 2,05,880.00
(f) Other Expenses
1 Impairment of non-current assets, net 25,750.00 35,180.00
2 Other Expenses 2,24,690.00 8,66,480.00
Total other expenses 2,50,440.00 9,01,660.00
Total expenses 7,82,670.00 29,67,930.00
3 Total profit before exceptional items and tax 19,510.00 5,37,930.00
4 Exceptional items 0.00 0.00
5 Total profit before tax 19,510.00 5,37,930.00
6 Tax expense
7 Current tax (2,370.00) 1,39,450.00
8 Deferred tax 210.00 (15,940.00)
9 Total tax expenses (2,160.00) 1,23,510.00
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 21,670.00 4,14,420.00
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 460.00 1,340.00
16 Total profit (loss) for period 22,130.00 4,15,760.00
17 Other comprehensive income net of taxes 24,580.00 73,950.00
18 Total Comprehensive Income for the period 46,710.00 4,89,710.00
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent 22,090.00 4,19,600.00
Total profit or loss, attributable to non-controlling interests 40.00 (3,840.00)
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent 46,670.00 4,93,550.00
Total comprehensive income for the period attributable to owners of parent non-controlling interests 40.00 (3,840.00)
21 Details of equity share capital
Paid-up equity share capital 8,350.00 8,350.00
Face value of equity share capital 1 1
27 Details of debt securities
22 Reserves excluding revaluation reserve 37,80,800.00
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 2.65 50.41
Diluted earnings (loss) per share from continuing operations 2.65 50.35
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 2.65 50.41
Diluted earnings (loss) per share from continuing and discontinued operations 2.65 50.35
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2025
Date of end of reporting period 31-03-2026
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Consolidated
Assets
1 Non-current assets
Property, plant and equipment 10,07,780.00
Capital work-in-progress 1,46,020.00
Investment property 0.00
Goodwill 1,47,970.00
Other intangible assets 10,50,580.00
Intangible assets under development 0.00
Biological assets other than bearer plants 0.00
Investments accounted for using equity method 56,730.00
Non-current financial assets
Non-current investments 89,420.00
Trade receivables, non-current 0.00
Loans, non-current 0.00
Other non-current financial assets
1 Other financial assets 29,170.00
Total of other non-current financial assets 29,170.00
Total non-current financial assets 1,18,590.00
Deferred tax assets (net) 2,21,900.00
Other non-current assets
1 Tax assets, net 35,030.00
2 Other non-current assets 9,810.00
Total of other non-current assets 44,840.00
Total non-current assets 27,94,410.00
2 Current assets
Inventories 7,65,340.00
Current financial asset
Current investments 3,82,330.00
Trade receivables, current 10,12,340.00
Cash and cash equivalents 1,53,680.00
Bank balance other than cash and cash equivalents 1,81,190.00
Loans, current 0.00
Other current financial assets
Total of other current financial assets 2,24,100.00
Total current financial assets 19,53,640.00
Current tax assets (net) 0.00
Other current assets
1 Other current assets 2,98,950.00
Total of other current assets 2,98,950.00
Total current assets 30,17,930.00
3 Non-current assets classified as held for sale 0.00
4 Regulatory deferral account debit balances and related deferred tax Assets 0.00
Total assets 58,12,340.00
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 8,350.00
Other equity 37,80,800.00
Total equity attributable to owners of parent 37,89,150.00
Non controlling interest 33,940.00
Total equity 38,23,090.00
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 0.00
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0.00
Total Trade payable 0.00
Other non-current financial liabilities
1 Lease liabilities 1,22,030.00
2 Other financial liabilities 4,320.00
Total of other non-current financial liabilities 1,26,350.00
Total non-current financial liabilities 1,26,350.00
Provisions, non-current 3,380.00
Deferred tax liabilities (net) 1,54,670.00
Deferred government grants, Non-current 0.00
Other non-current liabilities
1 Other non-current liabilities 30,110.00
Total of other non-current liabilities 30,110.00
Total non-current liabilities 3,14,510.00
Current liabilities
Current financial liabilities
Borrowings, current 6,29,350.00
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 3,340.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 3,00,450.00
Total Trade payable 3,03,790.00
Other current financial liabilities
1 Lease liabilities 22,030.00
2 Derivative financial instruments 68,980.00
3 Other financial liabilities 4,00,850.00
Total of other current financial liabilities 4,91,860.00
Total current financial liabilities 14,25,000.00
Other current liabilities 1,19,210.00
1 Other current liabilities 1,19,210.00
Total of other current liabilities 1,19,210.00
Provisions, current 87,000.00
Current tax liabilities (Net) 43,530.00
Deferred government grants, Current
Total current liabilities 16,74,740.00
3 Liabilities directly associated with assets in disposal group classified as held for sale 0.00
4 Regulatory deferral account credit balances and related deferred tax liability 0.00
Total liabilities 19,89,250.00
Total equity and liabilites 58,12,340.00
Disclosure of notes on assets and liabilities



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-01-2026 01-04-2025
Date of end of reporting period 31-03-2026 31-03-2026
Whether results are audited or unaudited Audited Audited
Nature of report standalone or consolidated Consolidated Consolidated
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
1 a) Global Generics 6,59,250.00 29,94,600.00
2 b) Pharmaceutical Services and Active Ingredients 1,12,470.00 4,26,720.00
3 c) Others 2,430.00 21,400.00
Total Segment Revenue 7,74,150.00 34,42,720.00
Less: Inter segment revenue 19,510.00 72,700.00
Revenue from operations 7,54,640.00 33,70,020.00
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
1 a) Global Generics 3,17,680.00 16,96,960.00
2 b) Pharmaceutical Services and Active Ingredients 18,490.00 60,020.00
3 c) Others 740.00 15,810.00
Total Profit before tax 3,36,910.00 17,72,790.00
i. Finance cost 0.00 0.00
ii. Other Unallocable Expenditure net off Unallocable income 3,16,940.00 12,33,520.00
Profit before tax 19,970.00 5,39,270.00
3 (Segment Asset - Segment Liabilities)
Segment Asset
1 a) Global Generics 0.00 0.00
2 b) Pharmaceutical Services and Active Ingredients 0.00 0.00
3 c) Others 0.00 0.00
Total Segment Asset 0.00 0.00
Un-allocable Assets 0.00 0.00
Net Segment Asset 0.00 0.00
4 Segment Liabilities
Segment Liabilities
1 a) Global Generics 0.00 0.00
2 b) Pharmaceutical Services and Active Ingredients 0.00 0.00
3 c) Others 0.00 0.00
Total Segment Liabilities 0.00 0.00
Un-allocable Liabilities 0.00 0.00
Net Segment Liabilities 0.00 0.00
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-01-2026 01-04-2025
B Date of end of reporting period 31-03-2026 31-03-2026
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Consolidated Consolidated
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Items that will not be reclassified subsequently to profit or loss 1,680.00 1,430.00
Total Amount of items that will not be reclassified to profit and loss 1,680.00 1,430.00
2 Income tax relating to items that will not be reclassified to profit or loss 560.00 560.00
3 Amount of items that will be reclassified to profit and loss
1 Items that will be reclassified subsequently to profit or loss 21,670.00 69,160.00
Total Amount of items that will be reclassified to profit and loss 21,670.00 69,160.00
4 Income tax relating to items that will be reclassified to profit or loss (1,790.00) (3,920.00)
5 Total Other comprehensive income 24,580.00 73,950.00



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2025
B Date of end of reporting period 31-03-2026
C Whether results are audited or unaudited Audited
D Nature of report standalone or consolidated Consolidated
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 5,37,930.00
Adjustments for reconcile profit (loss)
Adjustments for finance costs 37,380.00
Adjustments for decrease (increase) in inventories (86,010.00)
Adjustments for decrease (increase) in trade receivables, current (67,220.00)
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets 0.00
Adjustments for decrease (increase) in other non-current assets 17,870.00
Adjustments for other financial assets, non-current 0.00
Adjustments for other financial assets, current 0.00
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current 27,900.00
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities 0.00
Adjustments for increase (decrease) in other non-current liabilities 0.00
Adjustments for depreciation and amortisation expense 2,05,880.00
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 35,180.00
Adjustments for provisions, current 75,170.00
Adjustments for provisions, non-current 0.00
Adjustments for other financial liabilities, current 0.00
Adjustments for other financial liabilities, non-current 0.00
Adjustments for unrealised foreign exchange losses gains (5,290.00)
Adjustments for dividend income 0.00
Adjustments for interest income 0.00
Adjustments for share-based payments 3,260.00
Adjustments for fair value losses (gains) (23,590.00)
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow (25,470.00)
Other adjustments to reconcile profit (loss) 0.00
Other adjustments for non-cash items 6,900.00
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) 2,01,960.00
Net cash flows from (used in) operations 7,39,890.00
Dividends received 0.00
Interest paid 0.00
Interest received (37,260.00)
Income taxes paid (refund) 1,35,260.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities 5,67,370.00
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 31,520.00
Other cash receipts from sales of equity or debt instruments of other entities 1,96,020.00
Other cash payments to acquire equity or debt instruments of other entities 4,67,180.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 510.00
Proceeds from sales of property, plant and equipment 3,090.00
Purchase of property, plant and equipment 2,33,060.00
Proceeds from sales of investment property 0.00
Purchase of investment property 0.00
Proceeds from sales of intangible assets 14,010.00
Purchase of intangible assets 1,50,990.00
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 0.00
Purchase of other long-term assets 0.00
Cash advances and loans made to other parties 0.00
Cash receipts from repayment of advances and loans made to other parties 0.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 0.00
Interest received 15,210.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) investing activities (6,54,930.00)
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 3,970.00
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 0.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 2,02,570.00
Repayments of borrowings 10.00
Payments of lease liabilities 12,630.00
Dividends paid 66,590.00
Interest paid 44,410.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) financing activities 82,900.00
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes (4,660.00)
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 12,410.00
Net increase (decrease) in cash and cash equivalents 7,750.00
Cash and cash equivalents cash flow statement at beginning of period 1,45,930.00
Cash and cash equivalents cash flow statement at end of period 1,53,680.00





Details of Impact of Audit Qualification

Amount in (Lakhs)

Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 S.R Batliboi & Associates LLP Yes 31-07-2027